Follow The Short Interest: What’s Propelling Cipher Pharmaceuticals Incorporated (NASDAQ:CPHR) After Higher Shorts Reported?

November 30, 2016 - By kentuckypostne   ·   0 Comments

Follow The Short Interest: What’s Propelling Cipher Pharmaceuticals Incorporated (NASDAQ:CPHR) After Higher Shorts Reported?

The stock of Cipher Pharmaceuticals Incorporated (NASDAQ:CPHR) registered an increase of 348.15% in short interest. CPHR’s total short interest was 48,400 shares in November as published by FINRA. Its up 348.15% from 10,800 shares, reported previously. With 8,600 shares average volume, it will take short sellers 6 days to cover their CPHR’s short positions. The short interest to Cipher Pharmaceuticals Incorporated’s float is 0.3%. The stock closed at $2.82 during the last session. It is down 53.62% since April 27, 2016 and is downtrending. It has underperformed by 58.85% the S&P500.

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The company has a market cap of $73.89 million. The Firm has a portfolio of commercial and late-stage products. It currently has negative earnings. It operates in the specialty pharmaceuticals segment.

Cipher Pharmaceuticals Inc (NASDAQ:CPHR) Ratings Coverage

Out of 2 analysts covering Cipher Pharma (NASDAQ:CPHR), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cipher Pharma has been the topic of 2 analyst reports since November 30, 2015 according to StockzIntelligence Inc. On Monday, November 30 the stock rating was initiated by CBIC with “Outperform”. The company was initiated on Monday, November 30 by IBC.

More news for Cipher Pharmaceuticals Inc (NASDAQ:CPHR) were recently published by: Prnewswire.com, which released: “Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors” on August 09, 2016. Streetinsider.com‘s article titled: “Cipher Pharma (CPHR) Will Delist from Nasdaq on Voluntary Basis” and published on November 29, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By kentuckypostne


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>